Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status

The current standard of care for patients with locally advanced head and neck squamous cell carcinoma (LAHNSCC) is concurrent chemoradiotherapy (CRT), although it is associated with frequent severe acute and late toxicities [1]. In the recent years there has been a growing interest in increasing the benefit/risk ratio in human papillomavirus (HPV)-positive patients [2,3]. Due to improved prognosis, CRT could be safely postponed in HPV positive patients, reducing toxicity while not jeopardizing survival.

from #ENT-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2tTl4jf